# Nuvation Bio Inc.: financial statements, quarterly

NUVB · NYSE · CIK 1811063 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nuvb.md) · [Financials](/companies/nuvb/financials.md) · [Filings](/companies/nuvb/filings.md) · [Insiders](/companies/nuvb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nuvb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-122402.md) | [0.0 d](/filings/0000950170-25-034903.md) | [0.0](/filings/0000950170-25-065712.md) | [1.4](/filings/0000950170-25-104626.md) | [0.7](/filings/0001193125-25-262605.md) | [5.7 d](/filings/0001193125-26-085584.md) | [3.1](/filings/0001193125-26-203964.md) | [4.8](/filings/0001193125-26-336646.md) | [13.1](/filings/0001193125-25-262605.md) | [41.9 d](/filings/0001193125-26-085584.md) | [83.2](/filings/0001193125-26-203964.md) | [31.7](/filings/0001193125-26-336646.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-065712.md) | [1.3](/filings/0000950170-25-104626.md) | [1.5](/filings/0001193125-25-262605.md) | [4.2 d](/filings/0000950170-25-034903.md) | [2.1](/filings/0000950170-25-065712.md) | [2.6](/filings/0000950170-25-104626.md) | [3.3](/filings/0001193125-25-262605.md) | not reported | not reported | not reported |
| Gross profit | $m | [0.0](/filings/0000950170-24-122402.md) | [0.0 d](/filings/0000950170-25-034903.md) | [0.0](/filings/0000950170-25-065712.md) | [0.1](/filings/0000950170-25-104626.md) | [(0.8)](/filings/0001193125-25-262605.md) | [1.5 d](/filings/0000950170-25-034903.md) | [1.0](/filings/0000950170-25-065712.md) | [2.3](/filings/0000950170-25-104626.md) | [9.8](/filings/0001193125-25-262605.md) | not reported | not reported | not reported |
| Research and development | $m | [18.6](/filings/0000950170-24-122402.md) | [15.4 d](/filings/0000950170-25-034903.md) | [12.8](/filings/0000950170-25-065712.md) | [29.2](/filings/0000950170-25-104626.md) | [27.7](/filings/0001193125-25-262605.md) | [29.3 d](/filings/0001193125-26-085584.md) | [24.6](/filings/0001193125-26-203964.md) | [27.4](/filings/0001193125-26-336646.md) | [28.8](/filings/0001193125-25-262605.md) | [34.3 d](/filings/0001193125-26-085584.md) | [35.0](/filings/0001193125-26-203964.md) | [30.7](/filings/0001193125-26-336646.md) |
| Selling, general and administrative | $m | [7.8](/filings/0000950170-24-122402.md) | [5.5 d](/filings/0000950170-25-034903.md) | [7.4](/filings/0000950170-25-065712.md) | [16.2](/filings/0000950170-25-104626.md) | [19.6](/filings/0001193125-25-262605.md) | [26.1 d](/filings/0001193125-26-085584.md) | [35.4](/filings/0001193125-26-203964.md) | [38.5](/filings/0001193125-26-336646.md) | [37.4](/filings/0001193125-25-262605.md) | [40.3 d](/filings/0001193125-26-085584.md) | [38.3](/filings/0001193125-26-203964.md) | [42.6](/filings/0001193125-26-336646.md) |
| Operating income | $m | [(26.3)](/filings/0000950170-24-122402.md) | [(20.8) d](/filings/0000950170-25-034903.md) | [(20.2)](/filings/0000950170-25-065712.md) | [(470)](/filings/0000950170-25-104626.md) | [(48.1)](/filings/0001193125-25-262605.md) | [(53.9) d](/filings/0001193125-26-085584.md) | [(59.0)](/filings/0001193125-26-203964.md) | [(63.6)](/filings/0001193125-26-336646.md) | [(56.4)](/filings/0001193125-25-262605.md) | [(34.0) d](/filings/0001193125-26-085584.md) | [3.9](/filings/0001193125-26-203964.md) | [(51.0)](/filings/0001193125-26-336646.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-122402.md) | [0.0 d](/filings/0000950170-25-034903.md) | [0.0](/filings/0000950170-25-065712.md) | [0.1](/filings/0000950170-24-090347.md) | [0.1](/filings/0001193125-25-262605.md) | [0.1 d](/filings/0001193125-26-085584.md) | [0.1](/filings/0001193125-26-203964.md) | [0.4](/filings/0001193125-26-336646.md) | [5.1](/filings/0001193125-25-262605.md) | [5.0 d](/filings/0001193125-26-085584.md) | [6.7](/filings/0001193125-26-203964.md) | [6.8](/filings/0001193125-26-336646.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122402.md) | [0.0 d](/filings/0000950170-25-034903.md) | [0.0](/filings/0000950170-25-065712.md) | [0.0](/filings/0000950170-25-104626.md) | [0.0](/filings/0001193125-25-262605.md) | [0.0 d](/filings/0001193125-26-085584.md) | [0.0](/filings/0001193125-26-203964.md) | [0.0](/filings/0001193125-26-336646.md) | [0.0](/filings/0001193125-25-262605.md) | [0.0 d](/filings/0001193125-26-085584.md) | [0.0](/filings/0001193125-26-203964.md) | [0.0](/filings/0001193125-26-336646.md) |
| Net income | $m | [(19.6)](/filings/0000950170-24-122402.md) | [(13.8) d](/filings/0000950170-25-034903.md) | [(14.8)](/filings/0001193125-25-262605.md) | [(462)](/filings/0001193125-25-262605.md) | [(41.2)](/filings/0001193125-25-262605.md) | [(49.4) d](/filings/0001193125-26-085584.md) | [(53.2)](/filings/0001193125-26-336646.md) | [(59.0)](/filings/0001193125-26-336646.md) | [(55.8)](/filings/0001193125-25-262605.md) | [(36.6) d](/filings/0001193125-26-085584.md) | [5.4](/filings/0001193125-26-336646.md) | [(62.8)](/filings/0001193125-26-336646.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0000950170-24-122402.md) | not reported | [(0.07)](/filings/0000950170-25-065712.md) | [(1.89)](/filings/0000950170-25-104626.md) | [(0.15)](/filings/0001193125-25-262605.md) | not reported | [(0.16)](/filings/0001193125-26-203964.md) | [(0.17)](/filings/0001193125-26-336646.md) | [(0.16)](/filings/0001193125-25-262605.md) | not reported | [0.01](/filings/0001193125-26-203964.md) | [(0.18)](/filings/0001193125-26-336646.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0000950170-24-122402.md) | not reported | [(0.07)](/filings/0000950170-25-065712.md) | [(1.89)](/filings/0000950170-25-104626.md) | [(0.15)](/filings/0001193125-25-262605.md) | not reported | [(0.16)](/filings/0001193125-26-203964.md) | [(0.17)](/filings/0001193125-26-336646.md) | [(0.16)](/filings/0001193125-25-262605.md) | not reported | [0.02](/filings/0001193125-26-203964.md) | [(0.18)](/filings/0001193125-26-336646.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.4](/filings/0000950170-23-058253.md) | [42.6](/filings/0000950170-25-034903.md) | [34.5](/filings/0000950170-24-059622.md) | [34.3](/filings/0000950170-24-090347.md) | [30.0](/filings/0000950170-24-122402.md) | [35.7](/filings/0001193125-26-085584.md) | [48.0](/filings/0000950170-25-065712.md) | [248](/filings/0000950170-25-104626.md) | [98.9](/filings/0001193125-25-262605.md) | [164](/filings/0001193125-26-336646.md) | [125](/filings/0001193125-26-203964.md) | [259](/filings/0001193125-26-336646.md) |
| Current assets | $m | [625](/filings/0000950170-23-058253.md) | [616](/filings/0000950170-25-034903.md) | [608](/filings/0000950170-24-059622.md) | [587](/filings/0000950170-24-090347.md) | [565](/filings/0000950170-24-122402.md) | [526](/filings/0001193125-26-085584.md) | [476](/filings/0000950170-25-065712.md) | [623](/filings/0000950170-25-104626.md) | [578](/filings/0001193125-25-262605.md) | [572](/filings/0001193125-26-336646.md) | [592](/filings/0001193125-26-203964.md) | [726](/filings/0001193125-26-336646.md) |
| Total assets | $m | [631](/filings/0000950170-23-058253.md) | [621](/filings/0000950170-25-034903.md) | [613](/filings/0000950170-24-059622.md) | [595](/filings/0000950170-24-090347.md) | [572](/filings/0000950170-24-122402.md) | [541](/filings/0001193125-26-085584.md) | [492](/filings/0000950170-25-065712.md) | [647](/filings/0000950170-25-104626.md) | [602](/filings/0001193125-25-262605.md) | [595](/filings/0001193125-26-336646.md) | [610](/filings/0001193125-26-203964.md) | [745](/filings/0001193125-26-336646.md) |
| Current liabilities | $m | [16.1](/filings/0000950170-23-058253.md) | [14.0](/filings/0000950170-25-034903.md) | [15.8](/filings/0000950170-24-059622.md) | [51.1](/filings/0000950170-24-090347.md) | [59.0](/filings/0000950170-24-122402.md) | [58.2](/filings/0001193125-26-085584.md) | [52.8](/filings/0000950170-25-065712.md) | [66.4](/filings/0000950170-25-104626.md) | [68.1](/filings/0001193125-25-262605.md) | [82.2](/filings/0001193125-26-336646.md) | [79.5](/filings/0001193125-26-203964.md) | [86.8](/filings/0001193125-26-336646.md) |
| Total liabilities | $m | [19.3](/filings/0000950170-23-058253.md) | [16.4](/filings/0000950170-25-034903.md) | [19.1](/filings/0000950170-24-059622.md) | [62.7](/filings/0000950170-24-090347.md) | [68.9](/filings/0000950170-24-122402.md) | [76.8](/filings/0001193125-26-085584.md) | [73.0](/filings/0000950170-25-065712.md) | [274](/filings/0000950170-25-104626.md) | [276](/filings/0001193125-25-262605.md) | [289](/filings/0001193125-26-336646.md) | [291](/filings/0001193125-26-203964.md) | [491](/filings/0001193125-26-336646.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [47.0](/filings/0000950170-25-104626.md) | [47.1](/filings/0001193125-25-262605.md) | [47.2](/filings/0001193125-26-085584.md) | [47.3](/filings/0001193125-26-203964.md) | [243](/filings/0001193125-26-336646.md) |
| Short-term borrowings | $m | not reported | [0.0](/filings/0000950170-25-034903.md) | not reported | [11.6](/filings/0000950170-24-090347.md) | [8.4](/filings/0000950170-24-122402.md) | [6.3](/filings/0001193125-26-085584.md) | [5.7](/filings/0000950170-25-065712.md) | [5.6](/filings/0000950170-25-104626.md) | [5.6](/filings/0001193125-25-262605.md) | [5.7](/filings/0001193125-26-336646.md) | [5.8](/filings/0001193125-26-203964.md) | [5.9](/filings/0001193125-26-336646.md) |
| Shareholders' equity | $m | [612](/filings/0000950170-24-122402.md) | [605](/filings/0001193125-26-085584.md) | [594](/filings/0001193125-25-262605.md) | [257](/filings/0001193125-25-262605.md) | [503](/filings/0001193125-25-262605.md) | [464](/filings/0001193125-26-336646.md) | [419](/filings/0001193125-26-336646.md) | [373](/filings/0001193125-26-336646.md) | [326](/filings/0001193125-25-262605.md) | [306](/filings/0001193125-26-336646.md) | [320](/filings/0001193125-26-336646.md) | [254](/filings/0001193125-26-336646.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.2) d](/filings/0000950170-24-122402.md) | [(15.0) d](/filings/0000950170-25-034903.md) | [(15.7)](/filings/0000950170-25-065712.md) | [(37.3) d](/filings/0000950170-25-104626.md) | [(31.1) d](/filings/0001193125-25-262605.md) | [(46.3) d](/filings/0001193125-26-085584.md) | [(42.6)](/filings/0001193125-26-203964.md) | [(48.2) d](/filings/0001193125-26-336646.md) | [(52.9) d](/filings/0001193125-25-262605.md) | [(29.7) d](/filings/0001193125-26-085584.md) | [5.1](/filings/0001193125-26-203964.md) | [(43.0) d](/filings/0001193125-26-336646.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [218](/filings/0000950170-23-058253.md) | [219](/filings/0000950170-24-059622.md) | [219](/filings/0000950170-24-090347.md) | [219](/filings/0000950170-24-122402.md) | [219](/filings/0000950170-25-065712.md) | [245](/filings/0000950170-25-104626.md) | [274](/filings/0001193125-25-262605.md) | [339](/filings/0001193125-26-203964.md) | [341](/filings/0001193125-26-336646.md) | [342](/filings/0001193125-25-262605.md) | [378](/filings/0001193125-26-203964.md) | [349](/filings/0001193125-26-336646.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 351,123,233 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336646.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.